ZYME

SEC source: 0000899243-23-001216 · doc4.xml · derivative · entry 2

Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,500

Underlying: Common Stock · 51,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on January 5, 2024.

F3 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on January 5, 2024.

SEC source: 0000899243-23-001216 · doc4.xml · derivative · entry 1

Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires 2033-01-04

F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.

SEC source: 0000899243-22-039328 · doc4.xml · derivative · entry 1

Galbraith Kenneth · CIK 0001567045 · Director · Chair & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2025-12-22

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F2 · derivative.exercise_date: The RSUs vest on December 22, 2025.

F2 · derivative.expiration_date: The RSUs vest on December 22, 2025.

SEC source: 0000899243-22-039327 · doc4.xml · derivative · entry 1

Sacks Natalie · CIK 0001683811 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022.

SEC source: 0000899243-22-039322 · doc4.xml · derivative · entry 1

Hillan Kenneth J. · CIK 0001600359 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022.

SEC source: 0000899243-22-039326 · doc4.xml · derivative · entry 1

Mahony Susan · CIK 0001463321 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022.

SEC source: 0000899243-22-039321 · doc4.xml · derivative · entry 1

RENTON HOLLINGS · CIK 0001187333 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022.

SEC source: 0000899243-22-039324 · doc4.xml · derivative · entry 1

Zoth Lota S. · CIK 0001278219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022.

SEC source: 0000899243-22-039323 · doc4.xml · derivative · entry 1

Neu Kelvin · CIK 0001554699 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022.

SEC source: 0000899243-22-039325 · doc4.xml · derivative · entry 1

Cox Troy · CIK 0001696923 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-12-20

F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022.

SEC source: 0000899243-22-038516 · doc4.xml · derivative · entry 3

Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,550

Underlying: Common Shares · 1,550 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F5 · derivative.exercise_date: The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022.

F5 · derivative.expiration_date: The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022.

SEC source: 0000899243-22-038516 · doc4.xml · nonDerivative · entry 2

Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,333

F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.99 to $6.035, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-22-038516 · doc4.xml · nonDerivative · entry 1

Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,220

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents shares of common stock issued upon vesting of one half of the restricted stock units ("RSUs") granted on December 10, 2021.

SEC source: 0000899243-22-039332 · doc4a.xml · derivative · entry 3

Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,550

Underlying: Common Shares · 1,550 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F5 · derivative.exercise_date: The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022.

F5 · derivative.expiration_date: The RSUs were granted on December 10, 2021 and vest in two equal annual instalments beginning on December 12, 2022.

SEC source: 0000899243-22-039332 · doc4a.xml · nonDerivative · entry 2

Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,333

F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.99 to $6.035, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-22-039332 · doc4a.xml · nonDerivative · entry 1

Astle Christopher · CIK 0001915257 · SVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,220

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents shares of common stock issued upon vesting of one half of the restricted stock units ("RSUs") granted on December 10, 2021.

SEC source: 0000899243-22-035813 · doc4.xml · derivative · entry 3

Josephson Neil · CIK 0001864141 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,772

Underlying: Common Shares · 5,885 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F5 · derivative.exercise_date: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022.

F5 · derivative.expiration_date: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022.

SEC source: 0000899243-22-035813 · doc4.xml · nonDerivative · entry 2

Josephson Neil · CIK 0001864141 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,449

F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-22-035813 · doc4.xml · nonDerivative · entry 1

Josephson Neil · CIK 0001864141 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,924

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021.

SEC source: 0000899243-22-039331 · doc4a.xml · derivative · entry 3

Josephson Neil · CIK 0001864141 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,772

Underlying: Common Shares · 5,885 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F5 · derivative.exercise_date: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022.

F5 · derivative.expiration_date: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022.

SEC source: 0000899243-22-039331 · doc4a.xml · nonDerivative · entry 2

Josephson Neil · CIK 0001864141 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,449

F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-22-039331 · doc4a.xml · nonDerivative · entry 1

Josephson Neil · CIK 0001864141 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,924

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021.

SEC source: 0001104659-22-109454 · tm2228333-3_4seq1.xml · nonDerivative · entry 1

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 6,075,918

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.89 to $5.18, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles and separately managed accounts managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-22-109481 · tm2228443-1_4aseq1.xml · nonDerivative · entry 1

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 6,075,918

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.89 to $5.18, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles and separately managed accounts managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.